Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, progesterone (Utrogestan® Vaginal®) cannot be endorsed for use within NHS Wales for the supplementation of the luteal phase during assisted reproductive technology (ART) cycles. |
||
|
||
Medicine details |
||
| Medicine name | progesterone (Utrogestan® Vaginal) | |
| Formulation | 200 mg vaginal capsuleS | |
| Reference number | 2477 | |
| Indication | For the supplementation of the luteal phase during assisted reproductive technology (ART) cycles. |
|
| Company | Marlborough Pharmaceuticals | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 26/02/2014 | |
| Date of issue | 27/02/2014 | |